88 related articles for article (PubMed ID: 2572301)
21. Dynorphin A-(1-13) potently improves galanin-induced impairment of memory processes in mice.
Kameyama T; Ukai M; Miura M
Neuropharmacology; 1994 Oct; 33(10):1167-9. PubMed ID: 7532287
[TBL] [Abstract][Full Text] [Related]
22. Opioid and non-opioid behavioral actions of dynorphin A and the dynorphin analogue DAKLI.
Trujillo KA; Akil H
NIDA Res Monogr; 1990; 105():397-8. PubMed ID: 1678871
[No Abstract] [Full Text] [Related]
23. Behavioral effects of dynorphin 1-13 in the mouse and rat: initial observations.
Walker JM; Katz RJ; Akil H
Peptides; 1980; 1(4):341-5. PubMed ID: 7301637
[TBL] [Abstract][Full Text] [Related]
24. Dynorphin A-(1-13) potently improves the impairment of spontaneous alternation performance induced by the mu-selective opioid receptor agonist DAMGO in mice.
Itoh J; Ukai M; Kameyama T
J Pharmacol Exp Ther; 1994 Apr; 269(1):15-21. PubMed ID: 7909556
[TBL] [Abstract][Full Text] [Related]
25. Ganglioside GM1 counteracts the enhancing effects of subacute toluene exposure on apomorphine-induced locomotor activity.
von Euler G; Ogren SO; Fuxe K; Gustafsson JA
Toxicol Lett; 1992 Nov; 63(2):165-9. PubMed ID: 1455448
[TBL] [Abstract][Full Text] [Related]
26. Dynorphin A (1-13) in the brain suppresses epinephrine-induced ventricular premature complexes and ventricular tachyarrhythmias.
Rabkin SW
Regul Pept; 1992 Sep; 41(2):95-107. PubMed ID: 1279757
[TBL] [Abstract][Full Text] [Related]
27. Des-tyrosine(1) dynorphin A-(2-13) improves carbon monoxide-induced impairment of learning and memory in mice.
Hiramatsu M; Inoue K
Brain Res; 2000 Mar; 859(2):303-10. PubMed ID: 10719078
[TBL] [Abstract][Full Text] [Related]
28. Intrathecal morphine-3-glucuronide-induced nociceptive behavior via Delta-2 opioid receptors in the spinal cord.
Komatsu T; Katsuyama S; Nagase H; Mizoguchi H; Sakurada C; Tsuzuki M; Sakurada S; Sakurada T
Pharmacol Biochem Behav; 2016 Jan; 140():68-74. PubMed ID: 26476133
[TBL] [Abstract][Full Text] [Related]
29. Behavioral changes induced by stressful situations: effects of enkephalins, dynorphin, and their interactions.
Katoh A; Nabeshima T; Kameyama T
J Pharmacol Exp Ther; 1990 May; 253(2):600-7. PubMed ID: 1971017
[TBL] [Abstract][Full Text] [Related]
30. Effects of dynorphin A (1-13) on carbon monoxide-induced delayed amnesia in mice.
Hiramatsu M; Sasaki M; Nabeshima T; Kameyama T
Pharmacol Biochem Behav; 1997 Jan; 56(1):73-9. PubMed ID: 8981612
[TBL] [Abstract][Full Text] [Related]
31. Long-lasting antinociceptive effects of a novel dynorphin analogue, Tyr-D-Ala-Phe-Leu-Arg psi (CH(2)NH) Arg-NH(2), in mice.
Hiramatsu M; Inoue K; Ambo A; Sasaki Y; Kameyama T
Br J Pharmacol; 2001 Apr; 132(8):1948-56. PubMed ID: 11309268
[TBL] [Abstract][Full Text] [Related]
32. Influence of dynorphin A (1-13) and dynorphin A (1-10) amide on stress-induced analgesia.
Starec M; Rosina J; Málek J; Krsiak M
Physiol Res; 1996; 45(6):433-8. PubMed ID: 9085373
[TBL] [Abstract][Full Text] [Related]
33. Dynorphin A and related peptides administered intrathecally in the rat: a search for putative kappa opiate receptor activity.
Stevens CW; Yaksh TL
J Pharmacol Exp Ther; 1986 Sep; 238(3):833-8. PubMed ID: 2875172
[TBL] [Abstract][Full Text] [Related]
34. Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions.
Kreek MJ; Schluger J; Borg L; Gunduz M; Ho A
J Pharmacol Exp Ther; 1999 Jan; 288(1):260-9. PubMed ID: 9862779
[TBL] [Abstract][Full Text] [Related]
35. Comparative study of the behavioral changes evoked by d-amphetamine and apomorphine in adult cats. Dose-response relationship.
Motles E; Martinez I; Concha E; Mejias B; Torres P
Pharmacol Biochem Behav; 1989 May; 33(1):115-21. PubMed ID: 2780770
[TBL] [Abstract][Full Text] [Related]
36. Dynorphin A-(1-13) markedly improves scopolamine-induced impairment of spontaneous alternation performance in mice.
Itoh J; Ukai M; Kameyama T
Eur J Pharmacol; 1993 Jun; 236(3):341-5. PubMed ID: 8102969
[TBL] [Abstract][Full Text] [Related]
37. Dynorphin-(1-13) is a potent in vivo suppressor of vasopressin levels in the rat.
Haaf JA; Maigret C; Andringa-Bakker EA; van Wimersma Greidanus TB
Acta Endocrinol (Copenh); 1987 Jan; 114(1):96-101. PubMed ID: 2880444
[TBL] [Abstract][Full Text] [Related]
38. Dynorphin-related peptides cause motor dysfunction in the rat through a non-opiate action.
Faden AI; Jacobs TP
Br J Pharmacol; 1984 Feb; 81(2):271-6. PubMed ID: 6142741
[TBL] [Abstract][Full Text] [Related]
39. Cholinergic blockade with scopolamine in adult cats. Effects on the behaviors evoked by apomorphine and amphetamine.
Motles E; Gómez A; Tetas M; González M; Acuña C
Prog Neuropsychopharmacol Biol Psychiatry; 1992 Mar; 16(2):223-35. PubMed ID: 1579638
[TBL] [Abstract][Full Text] [Related]
40. Intracerebroventricular physostigmine-induced analgesia: enhancement by naloxone, beta-funaltrexamine and nor-binaltorphimine and antagonism by dynorphin A (1-17).
Fujimoto JM; Rady JJ
J Pharmacol Exp Ther; 1989 Dec; 251(3):1045-52. PubMed ID: 2574738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
